{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:4100"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:4100","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"The levels of angiogenic and anti-angiogenic molecule concentrations in pregnancy based disorders in the maternal and fetal circulation","abstract":"OBJECTIVE: To determine if preeclampsia (PE) and intrauterine growth restriction (IUGR) is associated with differing levels of angiogenic and anti-angiogenic growth factors in both maternal and fetal circulation and the effect of heme oxygenase-1 (HO-1) and honokiol, an AKT phosphorylation inhibitor, on endothelial cells (EC) on these anti-angiogenic growth factors. DESIGN: 1st test ; Nested case-controlled plasma samples from 165 pregnant patients assayed for soluble vascular endothelial growth factor 1 (sVEGFR-1) soluble endoglin (sEng), vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) in Spain during 2001-2007. 2nd test; knockdown of HO-1 on EC and assayed to observe the effects on sVEGFR-1 levels released. 3rd test; 24 hour treatment to honokiol, an extract from the magnolia tree, on endothelial cells to observe the effect on sVEGFR-1 and sEng release. RESULTS: In the PE specimens, maternal sVEGFR-1 levels increased more than 3-fold compared with gestational controls, fetals levels remained unchanged. The levels of sEng, and PlGF did not significantly change and the levels of VEGF 8-fold more than the controls. Free sVEGFR-1 was found to be in 4-fold excess in the PE state compared to the gestational control. siRNA of HO-1 was found to cause an elevation in VEGF activated sVEGFR-1 release. Honokiol was found to decrease VEGF activated sVEGFR-1 release with increasing concentration and increase sEng release in the presence of various growth factors. CONCLUSION: There is an excess of sVEGFR-1 present in PE. Heme oxygenase 1 mediates sVEGFR-1 release and honokiol decreases sVEGFR-1 release from EC.","abstract_html":"OBJECTIVE: To determine if preeclampsia (PE) and intrauterine growth restriction (IUGR) is associated with differing levels of angiogenic and anti-angiogenic growth factors in both maternal and fetal circulation and the effect of heme oxygenase-1 (HO-1) and honokiol, an AKT phosphorylation inhibitor, on endothelial cells (EC) on these anti-angiogenic growth factors. DESIGN: 1st test ; Nested case-controlled plasma samples from 165 pregnant patients assayed for soluble vascular endothelial growth factor 1 (sVEGFR-1) soluble endoglin (sEng), vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) in Spain during 2001-2007. 2nd test; knockdown of HO-1 on EC and assayed to observe the effects on sVEGFR-1 levels released. 3rd test; 24 hour treatment to honokiol, an extract from the magnolia tree, on endothelial cells to observe the effect on sVEGFR-1 and sEng release. RESULTS: In the PE specimens, maternal sVEGFR-1 levels increased more than 3-fold compared with gestational controls, fetals levels remained unchanged. The levels of sEng, and PlGF did not significantly change and the levels of VEGF 8-fold more than the controls. Free sVEGFR-1 was found to be in 4-fold excess in the PE state compared to the gestational control. siRNA of HO-1 was found to cause an elevation in VEGF activated sVEGFR-1 release. Honokiol was found to decrease VEGF activated sVEGFR-1 release with increasing concentration and increase sEng release in the presence of various growth factors. CONCLUSION: There is an excess of sVEGFR-1 present in PE. Heme oxygenase 1 mediates sVEGFR-1 release and honokiol decreases sVEGFR-1 release from EC.","abstract_has_math":false,"creators":["Afzal, Islam"],"institution":"University of Birmingham","degree_name":"m_ph","degree_level":"m_ph","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2013,"date_issued":"2013-07","date_published":"2013-07","updated_at":"2026-11-19T09:27:33Z","subjects":["RG Gynecology and obstetrics"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/4100/1/Afzal13_MPhil.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A4100","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["na"]},{"key":"dc:creator","label":"Author","values":["Afzal, Islam"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2013-07"]},{"key":"dc:date.issued","label":"Date","values":["2013-07"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","School of Clinical and Experimental Medicine, Academic Department of Obstetrics and Gynacology"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/4100/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["m_ph"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["m_ph"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["RG Gynecology and obstetrics"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/4100/1/Afzal13_MPhil.pdf","http://etheses.bham.ac.uk//id/eprint/4100/2/Decl_IS_Afzal13MPil.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["OBJECTIVE: To determine if preeclampsia (PE) and intrauterine growth restriction (IUGR) is associated with differing levels of angiogenic and anti-angiogenic growth factors in both maternal and fetal circulation and the effect of heme oxygenase-1 (HO-1) and honokiol, an AKT phosphorylation inhibitor, on endothelial cells (EC) on these anti-angiogenic growth factors. DESIGN: 1st test ; Nested case-controlled plasma samples from 165 pregnant patients assayed for soluble vascular endothelial growth factor 1 (sVEGFR-1) soluble endoglin (sEng), vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) in Spain during 2001-2007. 2nd test; knockdown of HO-1 on EC and assayed to observe the effects on sVEGFR-1 levels released. 3rd test; 24 hour treatment to honokiol, an extract from the magnolia tree, on endothelial cells to observe the effect on sVEGFR-1 and sEng release. RESULTS: In the PE specimens, maternal sVEGFR-1 levels increased more than 3-fold compared with gestational controls, fetals levels remained unchanged. The levels of sEng, and PlGF did not significantly change and the levels of VEGF 8-fold more than the controls. Free sVEGFR-1 was found to be in 4-fold excess in the PE state compared to the gestational control. siRNA of HO-1 was found to cause an elevation in VEGF activated sVEGFR-1 release. Honokiol was found to decrease VEGF activated sVEGFR-1 release with increasing concentration and increase sEng release in the presence of various growth factors. CONCLUSION: There is an excess of sVEGFR-1 present in PE. Heme oxygenase 1 mediates sVEGFR-1 release and honokiol decreases sVEGFR-1 release from EC."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public","staffonly"]},{"key":"dc:title","label":"Title","values":["The levels of angiogenic and anti-angiogenic molecule concentrations in pregnancy based disorders in the maternal and fetal circulation"]}]}],"canonical_facts":{"dc:contributor.sponsor":["na"],"dc:creator":["Afzal, Islam"],"dc:date":["2013-07"],"dc:date.issued":["2013-07"],"dc:description.abstract":["OBJECTIVE: To determine if preeclampsia (PE) and intrauterine growth restriction (IUGR) is associated with differing levels of angiogenic and anti-angiogenic growth factors in both maternal and fetal circulation and the effect of heme oxygenase-1 (HO-1) and honokiol, an AKT phosphorylation inhibitor, on endothelial cells (EC) on these anti-angiogenic growth factors. DESIGN: 1st test ; Nested case-controlled plasma samples from 165 pregnant patients assayed for soluble vascular endothelial growth factor 1 (sVEGFR-1) soluble endoglin (sEng), vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) in Spain during 2001-2007. 2nd test; knockdown of HO-1 on EC and assayed to observe the effects on sVEGFR-1 levels released. 3rd test; 24 hour treatment to honokiol, an extract from the magnolia tree, on endothelial cells to observe the effect on sVEGFR-1 and sEng release. RESULTS: In the PE specimens, maternal sVEGFR-1 levels increased more than 3-fold compared with gestational controls, fetals levels remained unchanged. The levels of sEng, and PlGF did not significantly change and the levels of VEGF 8-fold more than the controls. Free sVEGFR-1 was found to be in 4-fold excess in the PE state compared to the gestational control. siRNA of HO-1 was found to cause an elevation in VEGF activated sVEGFR-1 release. Honokiol was found to decrease VEGF activated sVEGFR-1 release with increasing concentration and increase sEng release in the presence of various growth factors. CONCLUSION: There is an excess of sVEGFR-1 present in PE. Heme oxygenase 1 mediates sVEGFR-1 release and honokiol decreases sVEGFR-1 release from EC."],"dc:format":["application/pdf"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/4100/1/Afzal13_MPhil.pdf","http://etheses.bham.ac.uk//id/eprint/4100/2/Decl_IS_Afzal13MPil.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","School of Clinical and Experimental Medicine, Academic Department of Obstetrics and Gynacology"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/4100/"],"dc:subject":["RG Gynecology and obstetrics"],"dcterms:accessrights":["public","staffonly"],"dc:title":["The levels of angiogenic and anti-angiogenic molecule concentrations in pregnancy based disorders in the maternal and fetal circulation"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["m_ph"],"dc:type.qualificationname":["m_ph"]},"updated_at":"2026-11-19T09:27:33Z"}